Cited 245 times in
Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김유선 | - |
dc.date.accessioned | 2015-04-23T16:44:38Z | - |
dc.date.available | 2015-04-23T16:44:38Z | - |
dc.date.issued | 2010 | - |
dc.identifier.issn | 1600-6135 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/101143 | - |
dc.description.abstract | Everolimus allows calcineurin-inhibitor reduction without loss of efficacy and may improve renal-transplant outcomes. In a 24-month, open-label study, 833 de novo renal-transplant recipients were randomized to everolimus 1.5 or 3.0 mg/day (target troughs 3-8 and 6-12 ng/mL, respectively) with reduced-exposure CsA, or mycophenolic acid (MPA) 1.44 g/day plus standard-exposure CsA. Patients received basiliximab +/- corticosteroids. The primary endpoint was composite efficacy failure (treated biopsy-proven acute rejection, graft loss, death or loss to follow-up) and the main safety endpoint was renal function (estimated glomerular filtration rate [eGFR], by Modification of Diet in Renal Disease [MDRD]) at Month 12 (last-observation-carried-forward analyses). Month 12 efficacy failure rates were noninferior in the everolimus 1.5 mg (25.3%) and 3.0 mg (21.9%) versus MPA (24.2%) groups. Mean eGFR at Month 12 was noninferior in the everolimus groups versus the MPA group (54.6 and 51.3 vs 52.2 mL/min/1.73 m(2) in the everolimus 1.5 mg, 3.0 mg and MPA groups, respectively; 95% confidence intervals for everolimus 1.5 mg and 3.0 mg vs MPA: -1.7, 6.4 and -5.0, 3.2, respectively). The overall incidence of adverse events was comparable between groups. The use of everolimus with progressive reduction in CsA exposure, up to 60% at 1 year, resulted in similar efficacy and renal function compared with standard-exposure CsA plus MPA | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 1401~1413 | - |
dc.relation.isPartOf | AMERICAN JOURNAL OF TRANSPLANTATION | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adrenal Cortex Hormones | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Antibodies, Monoclonal | - |
dc.subject.MESH | Biopsy | - |
dc.subject.MESH | Enzyme Inhibitors | - |
dc.subject.MESH | Everolimus | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunosuppressive Agents/pharmacology | - |
dc.subject.MESH | Kidney/drug effects | - |
dc.subject.MESH | Kidney/pathology | - |
dc.subject.MESH | Kidney/physiopathology | - |
dc.subject.MESH | Kidney Function Tests | - |
dc.subject.MESH | Kidney Transplantation/adverse effects | - |
dc.subject.MESH | Kidney Transplantation/methods* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Mycophenolic Acid/administration & dosage* | - |
dc.subject.MESH | Mycophenolic Acid/therapeutic use | - |
dc.subject.MESH | Recombinant Fusion Proteins | - |
dc.subject.MESH | Safety | - |
dc.subject.MESH | Sirolimus/adverse effects | - |
dc.subject.MESH | Sirolimus/analogs & derivatives | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학) | - |
dc.contributor.googleauthor | H. Tedesco Silva Jr | - |
dc.contributor.googleauthor | D. Cibrik | - |
dc.contributor.googleauthor | T. Johnston | - |
dc.contributor.googleauthor | E. Lackova | - |
dc.contributor.googleauthor | K. Mange | - |
dc.contributor.googleauthor | C. Panis | - |
dc.contributor.googleauthor | R. Walker | - |
dc.contributor.googleauthor | Z. Wang | - |
dc.contributor.googleauthor | G. Zibari | - |
dc.contributor.googleauthor | Y. S. Kim | - |
dc.identifier.doi | 10.1111/j.1600-6143.2010.03129.x | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00785 | - |
dc.relation.journalcode | J00121 | - |
dc.identifier.eissn | 1600-6143 | - |
dc.identifier.pmid | 20455882 | - |
dc.subject.keyword | Calcineurin inhibitor toxicity | - |
dc.subject.keyword | cyclosporine | - |
dc.subject.keyword | everolimus | - |
dc.subject.keyword | renal function | - |
dc.subject.keyword | renal transplantation | - |
dc.subject.keyword | ther-apeutic drug monitoring | - |
dc.contributor.alternativeName | Kim, Yu Seun | - |
dc.contributor.affiliatedAuthor | Kim, Yu Seun | - |
dc.citation.volume | 10 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1401 | - |
dc.citation.endPage | 1413 | - |
dc.identifier.bibliographicCitation | AMERICAN JOURNAL OF TRANSPLANTATION, Vol.10(6) : 1401-1413, 2010 | - |
dc.identifier.rimsid | 52094 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.